Table 4.
Effect size of the difference in [11C]NOP-1A VT in cocaine use disorder vs. healthy controls by sex
| Regions of interest | Males (d) |
Female (d) |
Effect size ratio (female/male) |
|---|---|---|---|
| Amygdala | 0.19 | 1.10 | 5.8 |
| Hippocampus | 0.37 | 1.27 | 3.4 |
| Midbrain | 0.62 | 1.33 | 2.1 |
| Ventral Striatum | 0.62 | 1.12 | 1.8 |
| Caudate | 0.16 | 0.85 | 5.3 |
| Putamen | 0.44 | 0.89 | 2.0 |
| Dorsolateral Prefrontal Cortex | 0.38 | 0.73 | 1.9 |
| Orbital Frontal Cortex | 0.45 | 0.77 | 1.7 |
| Medial Prefrontal Cortex | 0.35 | 0.77 | 2.2 |
| Anterior Cingulate Cortex | 0.57 | 0.70 | 1.2 |
| Cerebellum | 0.81 | 0.96 | 1.2 |
d is the Cohen’s effect size maximum likelihood estimation of the difference between cocaine use disorder and healthy controls